Amylyx Pharmaceuticals Long Term Debt

The latest long-term debt for AMLX is $4.5M as of March 2026. That compares with $330K in the prior-year period — up 1268.8% year over year. Investors often review this figure alongside Amylyx Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, AMLX's long-term debt moved from $330K to $4.5M — a 1268.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Amylyx Pharmaceuticals's operating scale or balance-sheet position.

A long-term debt figure of $4.5M for AMLX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AMLX's long-term debt ($4.5M), review year-over-year change from $330K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.